AgeX Therapeutics (NYSE:AGE) Stock Price Down 11.9%

AgeX Therapeutics, Inc. (NYSE:AGE) shares traded down 11.9% on Monday . The company traded as low as $11.10 and last traded at $11.10. 3,700 shares were traded during mid-day trading, a decline of 4% from the average session volume of 3,849 shares. The stock had previously closed at $12.60.

AgeX Therapeutics Stock Performance

The firm’s 50-day moving average is $3.67 and its 200 day moving average is $1.49. The firm has a market capitalization of $11.99 million, a PE ratio of -0.85 and a beta of 1.18.

Institutional Investors Weigh In On AgeX Therapeutics

A hedge fund recently raised its stake in AgeX Therapeutics stock. Sigma Planning Corp increased its stake in AgeX Therapeutics, Inc. (NYSE:AGE) by 57.9% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 286,425 shares of the company’s stock after acquiring an additional 105,040 shares during the period. Sigma Planning Corp owned approximately 0.75% of AgeX Therapeutics worth $110,000 as of its most recent SEC filing. 12.50% of the stock is currently owned by institutional investors and hedge funds.

About AgeX Therapeutics

AgeX Therapeutics, Inc, a biotechnology company, focuses on the development and commercialization of novel therapeutics targeting human aging and degenerative diseases in the United States. The company's lead cell-based therapeutic candidates in development include AGEX-BAT1, a cell therapy product candidate for the treatment of various age-related metabolic disorders, such as Type II adult-onset diabetes and obesity; and AGEX-VASC1, a cell-based therapy to restore vascular support in aged ischemic tissues, such as peripheral vascular disease and ischemic heart disease.